Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany

BACKGROUND: The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Delphina, Beyerlein, Andreas, Katz, Katharina, Hoelscher, Gabriele, Nennstiel, Uta, Liebl, Bernhard, Überla, Klaus, von Kries, Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570490/
https://www.ncbi.nlm.nih.gov/pubmed/34739520
http://dx.doi.org/10.1371/journal.pone.0259370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570490/
https://www.ncbi.nlm.nih.gov/pubmed/34739520
http://dx.doi.org/10.1371/journal.pone.0259370

Ejemplares similares